ストックスクリーナーアプリを入手
9.60
3.03%
-0.35
前日終値:
$9.95
開ける：
$9.79
24時間の取引高:
103.96K
Relative Volume:
0.43
時価総額：
$178.05M
収益：
$1.54M
当期純損益:
$-78.54M
株価収益率:
-1.6059
EPS:
-5.978
ネットキャッシュフロー:
$-64.50M
1週間 パフォーマンス:
-15.59%
1か月 パフォーマンス:
-8.89%
6か月 パフォーマンス:
-18.37%
1年 パフォーマンス:
+24.34%
1日の値動き範囲:
$9.545
$10.04
1週間の範囲:
$9.545
$12.40
52週間の値動き範囲:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.61 | 184.35M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
440.95 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.23 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
793.49 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.76 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.59 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | 開始されました | Wedbush | Outperform |
| 2024-07-22 | 再開されました | H.C. Wainwright | Buy |
| 2024-06-26 | 開始されました | B. Riley Securities | Buy |
| 2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
| 2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-03-26 | 開始されました | Nomura | Buy |
| 2019-04-05 | 開始されました | Jefferies | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-10-24 | 開始されました | B. Riley FBR | Buy |
| 2018-01-19 | 開始されました | Raymond James | Outperform |
| 2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 繰り返されました | Noble Financial | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Understanding Momentum Shifts in (CRBP) - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors - Moomoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Octagon/Dr. Jia report 0 shares in Corbus (CRBP) — Schedule 13G/A - Stock Titan
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board - Investing.com UK
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Board, Advances CRB-701 and CRB-913 Clinical Programs - Minichart
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates - TipRanks
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals appoints pharma industry veteran Brent Pfeiffenberger to board of directors - marketscreener.com
Cor appoints Brent Pfeiffenberger to board as independent director - TradingView
Corbus Pharmaceuticals (NASDAQ: CRBP) adds industry veteran to board and expands 2024 equity plan - Stock Titan
HC Wainwright Issues Positive Forecast for CRBP Earnings - MarketBeat
Brokers Offer Predictions for CRBP Q2 Earnings - MarketBeat
CRBP Maintained by Jefferies -- Price Target Lowered to $33.00 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. schedules corporate overview at RBC and Jefferies healthcare events - Traders Union
CRBP Maintained by Oppenheimer -- Price Target Lowered to $54.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP Reiterates by Guggenheim -- Price Target Maintained at $45 - GuruFocus
CRBP: All proposals passed, including annual advisory votes on executive compensation - TradingView
CRBP: All five proposals, including director elections and equity plan amendment, were approved by majority - TradingView
Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating - marketscreener.com
Corbus Pharmaceuticals Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - ChartMill
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.11, Implies 272% Upside - TradingView
Corbus Pharmaceuticals (CRBP) Advances Oncology and Obesity Prog - GuruFocus
Jefferies cuts Corbus Pharmaceuticals stock price target on HNSCC data By Investing.com - Investing.com Canada
Corbus Pharmaceuticals (NASDAQ: CRBP) posts larger Q1 2026 loss but ends quarter with $138M cash - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.44, Implies 275% Upside - TradingView
Corbus Pharmaceuticals Reports Q1 2026 Results: Advances in CRB-701 for Cancer and CRB-913 for Obesity, FDA Alignment, and Upcoming ASCO Data - Minichart
Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update - Traders Union
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook - TipRanks
Corbus Pharmaceuticals Releases First Quarter 2026 Financial Results and Corporate Update - geneonline.com
Corbus Pharmaceuticals 1Q Loss/Shr $1.23 >CRBP - Moomoo
Corbus (NASDAQ: CRBP) details Q1 loss, FDA alignment and obesity trial - Stock Titan
Corbus Pharmaceuticals Reports FDA Alignment and Positive Developments for CRB-701 and CRB-913 Programs - Quiver Quantitative
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals: Q1 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals 1Q Loss $23M >CRBP - Moomoo
Obesity and cancer drug trials hit key 2026 milestones at Corbus - Stock Titan
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals in Norwood - Boston Real Estate Times
Avoiding Lag: Real-Time Signals in (CRBP) Movement - Stock Traders Daily
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals at 500 River Ridge Drive in Norwood - Colliers
Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting - Traders Union
Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel - Stock Titan
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
1.93%
0.98%
大文字化:
|
ボリューム (24 時間):